Guanfacine for Alcohol Use Disorder (AUD)

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT06629259
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Guanfacine Extended Release (XR) — DRUG
    3mg tablet once daily
  • Placebo — DRUG
    placebo tablet once daily

Study Details

The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.

Key Dates

Start date
Oct 3, 2025
Status verified
May 2026
Primary completion
Aug 31, 2029
Completion
Sep 7, 2029

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Guanfacine Extended Release (XR)
    Participants receive guanfacine XR, 3mg tablet orally, once per day for 12 weeks
  • Placebo Comparator: Placebo
    Participants receive guanfacine XR, placebo tablet orally, once per day for 12 weeks

Primary Outcome Measure

Change in % number of days drinking [ Time Frame: five times daily during weeks 1, 2, 5, 6 and twice weekly through week 12 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
The Stark Neuroscience Building (Goodman Hall)IndianapolisIndiana46202
Helen C Fox, PhD
[email protected]
203-671-9643
Rutgers School of Health ProfessionalsNewarkNew Jersey07107
Suchismita Ray, PhD
[email protected]
Suchismita Ray, PhD

Find similar trials in Indianapolis, IN

By condition
Substance use disorder
By specialty
Behavioral healthAddiction medicine
By research site
The Stark Neuroscience Building (Goodman Hall)· Indianapolis, INRutgers School of Health Professionals· Newark, NJ

Related Studies